R.I.P FDA approved Alzheimer’s drug

An Alzheimer’s drug, called “Aduhelm” hit the pharmacies a few years ago and has since disappeared. It was tremendously controversial and caused turmoil at the FDA after three FDA advisory scientists quit their jobs after it was approved. It costs users $57,000 annually. But don’t be concerned, because two new FDA approved Alzheimer’s disease drugs aimed at reducing amyloid plaque in the brain are now on the market.  But is brain plaque really the cause of Alzheimer’s Disease?  As I have reported for several years, when looking for it, scientists commonly find fungus in the brains and tissues of Alzheimer’s Disease patients (1). Based on this shouldn’t the presence of fungus become one of the principal standards for diagnosing and treating Alzheimer’s Disease?   What has become evident in our understanding of Alzheimer’s Disease,  is the discovery that the amyloid protein, thought to be responsible for generating Alzheimer’s Disease symptoms for over 100 years, probably isn’t (2) involved in the cause of the disease.

Yet Aduhelm was approved by our FDA because it was an anti-amyloid drug. It has been said that the danger, lies in observing the effect and believing it is the cause, which is precisely what we seem to be guilty of in diagnosing Alzheimer’s Disease and other neurological diseases.  Doctors are good people and, in their hunger, to quickly relieve Alzheimer’s Disease symptoms, they tend to overlook the cause of disease in favor of 4-6 hours of relief with prescription drugs. Said the journal STAT in 2021, “Bad medicine: aducanumab is a lackluster drug with a high price tag.”  But don’t let an expensive lackluster drug interfere with the relationship that exists between the FDA and drug companies.

“There have also been controversies given that the FDA’s advisory committee had asked if the agency planned to leverage an accelerated approval pathway for the drug, which would rely on biomarker data—that the drug cleared beta-amyloid—and require post-marketing studies to prove clinical efficacy. The agency said no. The advisory committee voted against approval, but the agency approved the drug under an accelerated approval pathway.”  (3)

The point of this blog is to teach that no longer do the old standard safeguards exist when taking prescribed medications. Bad drugs seem to be getting into pharmacies at a rapid rate.  Be wise and know this. Share concerns with your doctor.

Sources

1. Scientific Reports at Nature.com

2. ScienceAdvances

3. BioSpace

Related Articles

Are Diabetes and Alzheimer’s Linked to Fungus?

Germs as the cause of Alzheimer’s disease?

Still have questions?

Join our LIVE Q&A stream every week if you would like to ask a question! Learn more about the live show and join in here: KTC Too! – Doug Kaufmann’s Know the Cause